• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Expert opinion on biological therapy >Tumor-specific allogeneic cells for cancer therapy.
【24h】

Tumor-specific allogeneic cells for cancer therapy.

机译：用于癌症治疗的肿瘤特异性同种异体细胞。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Adoptive cell transfer (ACT) therapy involves transfer of therapeutic lymphocytes to patients mostly for the treatment of cancer and viral infections. One modality to generate therapeutic lymphocytes is to genetically engineer them to express a chimeric antigen receptor (CAR) capable of recognizing the desired target. Current ACT approaches employ the patient's own (syngeneic) lymphocytes, which is both economically and technically challenging. Using foreign (allogeneic) lymphocytes in ACT is problematic because of the severe immunological reaction that occurs between genetically mismatched individuals. However, recently our group has developed a protocol, which allows for safe and effective ACT therapy in a murine model of metastatic disease using allogeneic T cells redirected with a human EGFR2euregulin (Her2eu)-specific CAR. Mild preconditioning of the recipient delayed the rejection of the allogeneic donor T cells such that they had enough time to destroy the tumor, but not enough to cause significant damage to the host. By modulating lymphocyte migration using FTY720, we were actually able to exploit the allogeneic anti-host reaction in order to augment therapeutic benefit while concurrently improving the safety of the treatment. Therefore, we suggest that CAR-based allogeneic ACT therapy could be universally used as a safe and potent 'off-the-shelf' treatment for cancer.
机译：过继细胞转移（ACT）治疗涉及将治疗性淋巴细胞转移给患者，主要是为了治疗癌症和病毒感染。产生治疗性淋巴细胞的一种方式是对它们进行基因工程改造，使其表达能够识别所需靶标的嵌合抗原受体（CAR）。当前的ACT方法使用患者自己的（同基因）淋巴细胞，这在经济和技术上都具有挑战性。由于遗传失配的个体之间会发生严重的免疫反应，因此在ACT中使用外来（同种异体）淋巴细胞存在问题。然而，最近我们的小组已经开发出一种方案，该方案允许使用同种人类EGFR2 /神经调节蛋白（Her2 / neu）特异性CAR重定向的同种T细胞在转移性疾病的鼠模型中进行安全有效的ACT治疗。受体的温和预处理会延迟异体供体T细胞的排斥，从而使它们有足够的时间破坏肿瘤，但不足以对宿主造成重大损害。通过使用FTY720调节淋巴细胞的迁移，我们实际上能够利用同种异体抗宿主反应，以增强治疗效果，同时提高治疗的安全性。因此，我们建议基于CAR的异基因ACT治疗可普遍用作安全有效的癌症“现成”治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号